129.42 +0.33 (0.26%)
Pre-Market: 6:16AM EST
|Bid||127.20 x 800|
|Ask||130.35 x 800|
|Day's Range||127.46 - 129.52|
|52 Week Range||118.62 - 148.99|
|Beta (3Y Monthly)||0.62|
|PE Ratio (TTM)||226.87|
|Forward Dividend & Yield||3.60 (2.81%)|
|1y Target Est||N/A|
are collaborating on a study of a new heart health program that combines a Johnson & Johnson app with the Apple Watch to detect irregular heartbeat rhythms. The research study hopes to find out whether the app and Apple Watch can help with early detection and diagnosis of atrial fibrillation, which affects about 33 million people worldwide, according to the two companies. "Through Apple Watch, people have been able to learn more about their heart health, including discovering they have AFib.
Johnson & Johnson said Thursday that it has joined with Apple Inc. on a research study that will test the Apple Watch’s ability to help detect early irregular heart conditions in certain people before something life-threatening happens. Janssen Pharmaceuticals Inc., which is a part of J&J’s family of research and development companies, will work on the study. The company will use its J&J-developed heart health monitoring app on the latest Apple Watch series.
Dozens of top cannabis companies presented at the Benzinga Cannabis Capital Conference, held Wednesday at the Eden Roc Miami Beach. The company moves the highest volume of oil in Canada — up to $10 million in extract in a month.
Johnson & Johnson's Janssen Pharmaceuticals Inc. is collaborating on a multi-year research study with Apple Inc. to look at improving outcomes for patients with atrial fibrillation, the companies announced Thursday. The study will investigate whether a heart health app by Johnson & Johnson, combined with Apple Watch's irregular rhythm notifications and ECG app, can accelerate diagnosis and improve outcomes for people with atrial fibrillation. Atrial fibrillation is a condition that affects 33 million people worldwide and can lead to blood clots, stroke and heart failure. The study will be based in the U.S., the companies said, and subjects will be individuals 65 years or older. Shares of Apple were down 0.5% in premarket trade Thursday and have fallen 1.8% in the year to date through Wednesday. Shares of Johnson & Johnson have fallen 0.8%, while the S&P 500 has gained 4.4% and the Dow Jones Industrial Average has gained 3.8%.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 16) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioDelivery ...
Johnson & Johnson (JNJ) closed the most recent trading day at $129.36, moving +0.84% from the previous trading session.
Avicanna focuses on several product categories, including plant-derived cannabinoid pharmaceuticals, phytotherapeutics, dermacosmetics and extracts. In 2017, Avicanna became the first marijuana company to be accepted into Johnson & Johnson (NYSE: JNJ)'s JLABS @ Toronto, an incubation life science center. Last year, the company acquired controlling interests in Sativa Nativa and Santa Marta Golden Hemp, in which it has 70-percent and 60-percent stakes, respectively.
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Have you ever watched a top five economy in terms of nominal GDP try to stay on it's feet as other "top fives" inflict harm not only upon each other, but upon themselves? You may recall that the export driven German economy had contracted q/q in Q3 2018. At growth of 1.5% for the year, the German economy grew at the slowest pace since 2013, but the implication, which is a far more significant takeaway would be that the engine behind Eurozone growth did not fall into recession in late 2018.
# Johnson & Johnson ### NYSE:JNJ View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for JNJ with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting JNJ. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $16.11 billion over the last one-month into ETFs that hold JNJ are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. JNJ credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
A top U.S. lawmaker launched an investigation into pharmaceutical industry pricing practices on Monday, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices. Representative Elijah Cummings, who chairs the House Oversight Committee, sent letters to 12 drugmakers seeking information on price increases, investment in research and development, and corporate strategies to preserve market share and pricing power, his office said in a statement.
House Democrats announced a sweeping investigation Monday of the pharmaceutical industry's pricing practices, jockeying for the upper hand with the Trump administration on an issue that concerns Americans across the political spectrum. Oversight and Reform Committee Chairman Elijah Cummings said he's sent letters to 12 major drugmakers seeking detailed information and documents about pricing practices for brand-name drugs to treat diseases including cancer, diabetes, kidney failure and nerve pain. Cummings, a Maryland Democrat, said he wants to find out why prices have increased so dramatically for some existing medications, as well as how drug companies determine the prices of newly introduced medicines.
AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.
Medical technology stalwarts Abbott Laboratories, Johnson & Johnson and Medtronic will likely face exchange-rate headwinds in 2019, an analyst said Friday. But he stayed bullish on medtech.
Vertex Pharmaceuticals is the IBD Stock Of The Day as the leading biotech stock broke out in above-average volume The biotech is a leader in treatments for cystic fibrosis, a lung disease.
Johnson & Johnson raised U.S. prices on around two dozen of its top selling prescription drugs. Yahoo Finance's Adam Shapiro, Julie Hyman and Andy Serwer discuss with Emily McCormick who gives the latest.